Found: 38
Select item for more details and to access through your institution.
A173 INNOVATIVE CARE FOR INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC: USE OF BEDSIDE INTESTINAL ULTRASOUND TO OPTIMIZE MANAGEMENT.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2021, v. 4, p. 184, doi. 10.1093/jcag/gwab002.171
- By:
- Publication type:
- Article
A155 REAL-WORLD USE OF CORTIMENT IN ULCERATIVE COLITIS: A POPULATION-BASED STUDY.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2021, v. 4, p. 161, doi. 10.1093/jcag/gwab002.153
- By:
- Publication type:
- Article
A123 DEFINING CROHN'S DISEASE STRICTURES USING INTESTINAL ULTRASOUND COMPARED TO HISTOPATHOLOGY.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2021, v. 4, p. 104, doi. 10.1093/jcag/gwab002.121
- By:
- Publication type:
- Article
A87 HEALTHCARE PROVIDER SATISFACTION WITH VIRTUAL CARE DELIVERY IN ALBERTA DURING THE COVID-19 PANDEMIC.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2021, v. 4, p. 57, doi. 10.1093/jcag/gwab002.085
- By:
- Publication type:
- Article
A80 IMPACT OF THE COVID-19 PANDEMIC IN IBD PATIENT CARE.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2021, v. 4, p. 48, doi. 10.1093/jcag/gwab002.078
- By:
- Publication type:
- Article
A92 PREVIOUS VIRTUAL CONSULTATION EXPERIENCE IS RELATED TO PRECEPTOR'S WILLINGNESS TO INVOLVE TRAINEES IN VIRTUAL CARE DURING THE COVID-19 PANDEMIC.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2021, v. 4, p. 65, doi. 10.1093/jcag/gwab002.090
- By:
- Publication type:
- Article
A18 DIETARY PREDICTORS OF BIOLOGICAL ACTIVITY IN CROHN'S DISEASE: A RETROSPECTIVE COHORT STUDY.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2021, v. 4, p. 23, doi. 10.1093/jcag/gwab002.017
- By:
- Publication type:
- Article
A216 UC NARRATIVE CANADIAN DATA – COMPARING PATIENT AND PHYSICIAN PERSPECTIVES ON COMMUNICATION AND MANAGEMENT OF ULCERATIVE COLITIS.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 422, doi. 10.1093/jcag/gwz006.215
- By:
- Publication type:
- Article
A202 TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 5.4 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 396, doi. 10.1093/jcag/gwz006.201
- By:
- Publication type:
- Article
A133 PEDIATRIC ONSET INFLAMMATORY BOWEL DISEASE IS NOT ASSOCIATED WITH MORE DISABILITY COMPARED TO ADULT ONSET DISEASE.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 266, doi. 10.1093/jcag/gwz006.132
- By:
- Publication type:
- Article
A124 IMPROVEMENT IN DISEASE ACTIVITY IS ASSOCIATED WITH LESS DISABILITY IN A PROSPECTIVE STUDY OF PEDIATRIC TRANSITION PATIENTS WITH IBD.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 249, doi. 10.1093/jcag/gwz006.123
- By:
- Publication type:
- Article
A122 COMBINATION BIOLOGIC THERAPY IN INFLAMMATORY BOWEL DISEASE: THE CALGARY EXPERIENCE.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 244, doi. 10.1093/jcag/gwz006.121
- By:
- Publication type:
- Article
A91 UNMET NEEDS OF INFLAMMATORY BOWEL DISEASE PATIENTS IN CANADA: RESULTS OF A WEB SURVEY.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 181, doi. 10.1093/jcag/gwz006.090
- By:
- Publication type:
- Article
A68 COST EFFECTIVENESS OF TIGHT CONTROL FOR CROHN'S DISEASE WITH ADALIMUMAB-BASED TREATMENT: ECONOMIC EVALUATION OF CALM TRIAL FROM CANADIAN PERSPECTIVE.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 136, doi. 10.1093/jcag/gwz006.067
- By:
- Publication type:
- Article
A31 GLOBAL BURDEN OF HOSPITALIZATION FOR PERSONS WITH IBD IN THE 21ST CENTURY: TIME TREND ANALYSES.
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 61, doi. 10.1093/jcag/gwz006.030
- By:
- Publication type:
- Article
A29 THE EVOLVING INCIDENCE OF INFLAMMATORY BOWEL DISEASE: WHAT WILL THE FUTURE HOLD?
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 56, doi. 10.1093/jcag/gwz006.028
- By:
- Publication type:
- Article
A13 PROTEINS AND FIBROSTENOTIC CROHN'S DISEASE; WHO SHOWED UP TO THE PARTY?
- Published in:
- Journal of the Canadian Association of Gastroenterology, 2019, v. 2, p. 26, doi. 10.1093/jcag/gwz006.012
- By:
- Publication type:
- Article
Reduction in surgical stoma rates in Crohn's disease: a population‐based time trend analysis.
- Published in:
- Colorectal Disease, 2019, v. 21, n. 11, p. 1279, doi. 10.1111/codi.14731
- By:
- Publication type:
- Article
Novel concepts in inflammatory bowel disease.
- Published in:
- British Medical Bulletin, 2014, v. 109, n. 1, p. 55, doi. 10.1093/bmb/ldt039
- By:
- Publication type:
- Article
Multimodal Immunosuppressant Therapy in Steroid-Refractory Common Variable Immunodeficiency Sprue: A Case Report Complicating Cytomegalovirus Infection.
- Published in:
- International Journal of Surgical Pathology, 2006, v. 14, n. 1, p. 101, doi. 10.1177/106689690601400120
- By:
- Publication type:
- Article
Systematic review with meta‐analysis: endoscopic and histologic placebo rates in induction and maintenance trials of ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 12, p. 1578, doi. 10.1111/apt.14672
- By:
- Publication type:
- Article
Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2018, v. 47, n. 2, p. 219, doi. 10.1111/apt.14420
- By:
- Publication type:
- Article
Editorial: different tests for different drugs in Crohn's disease, or different tests for different people?
- Published in:
- 2017
- By:
- Publication type:
- Editorial
The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 10, p. 1329, doi. 10.1111/apt.14040
- By:
- Publication type:
- Article
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2017, v. 45, n. 9, p. 1232, doi. 10.1111/apt.14016
- By:
- Publication type:
- Article
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 10, p. 1236, doi. 10.1111/apt.12499
- By:
- Publication type:
- Article
Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 9, p. 1002, doi. 10.1111/apt.12491
- By:
- Publication type:
- Article
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2013, v. 38, n. 5, p. 447, doi. 10.1111/apt.12407
- By:
- Publication type:
- Article
Commentary: detection of infliximab levels and anti-infliximab antibodies.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2013, v. 37, n. 1, p. 153, doi. 10.1111/apt.12107
- By:
- Publication type:
- Article
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2011, v. 34, n. 3, p. 306, doi. 10.1111/j.1365-2036.2011.04717.x
- By:
- Publication type:
- Article
Review article: defining remission in ulcerative colitis.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2011, v. 34, n. 2, p. 113, doi. 10.1111/j.1365-2036.2011.04701.x
- By:
- Publication type:
- Article
Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2010, v. 31, n. 12, p. 1296, doi. 10.1111/j.1365-2036.2010.04304.x
- By:
- Publication type:
- Article
Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2010, v. 31, n. 1, p. 20, doi. 10.1111/j.1365-2036.2009.04112.x
- By:
- Publication type:
- Article
Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2009, v. 30, n. 10, p. 977, doi. 10.1111/j.1365-2036.2009.04101.x
- By:
- Publication type:
- Article
Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2008, v. 28, n. 6, p. 674, doi. 10.1111/j.1365-2036.2008.03753.x
- By:
- Publication type:
- Article
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Adverse Events and Nocebo Effects in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Published in:
- Journal of Crohn's & Colitis, 2019, v. 13, n. 9, p. 1201, doi. 10.1093/ecco-jcc/jjz087
- By:
- Publication type:
- Article
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2015, v. 110, n. 9, p. 1324, doi. 10.1038/ajg.2015.233
- By:
- Publication type:
- Article